Home  |  Contact

UniProtKB/Swiss-Prot P06213: Variant p.Ile1023Phe

Insulin receptor
Gene: INSR
Variant information

Variant position:  1023
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Isoleucine (I) to Phenylalanine (F) at position 1023 (I1023F, p.Ile1023Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page



Sequence information

Variant position:  1023
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1382
The length of the canonical sequence.

Location on the sequence:   SDVFPCSVYVPDEWEVSREK  I TLLRELGQGSFGMVYEGNAR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SDVFPCSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNAR

Mouse                         SDVFPSSVYVPDEWEVPREKITLLRELGQGSFGMVYEGNAK

Rat                           SDVFPSSVYVPDEWEVPREKITLLRELGQGSFGMVYEGNAK

Xenopus laevis                SE-----VYIPDEWEVPRDKINLLRELGQGSFGMVYEGIAK

Caenorhabditis elegans        N------KYNADDWELRQDDVVLGQQCGEGSFGKVYLGTGN

Drosophila                    -------QYIPDDWEVLRENIIQLAPLGQGSFGMVYEGILK

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 763 – 1382 Insulin receptor subunit beta
Topological domain 980 – 1382 Cytoplasmic
Domain 1023 – 1298 Protein kinase
Binding site 1033 – 1033 ATP
Modified residue 1011 – 1011 Phosphotyrosine; by autocatalysis
Mutagenesis 1011 – 1011 Y -> A. Increases kinase activity.
Beta strand 1023 – 1031


Literature citations

In-frame exon 2 deletion in insulin receptor RNA in a family with extreme insulin resistance in association with defective insulin binding: a case report.
Moritz W.; Boeni-Schnetzler M.; Stevens W.; Froesch E.R.; Levy J.R.;
Eur. J. Endocrinol. 135:357-363(1996)
Cited for: VARIANT PHE-1023;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.